Citations

Clear

6274 citation(s) found for "To, Andrew".

Physiology and fast marathons
Hunter, Sandra K. , Jones, Andrew M. , Hunter, Sandra K , Jones, Andrew M , Joyner, Michael J. , Lucía, Alejandro

Mayo Clinic

Journal of Applied Physiology | January 16, 2020 | Volume: 128 | Issue: 4 | Pages: 1065-1068

10.1152/japplphysiol.00793.2019 | PMID 31944889 Get It

Pulmonary Pathology Society Perspective on the 2018 American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society Idiopathic Pulmonary Fibrosis Clinical Practice Guidelines
Allen, Timothy Craig, Attanoos, Richard , Borczuk, Alain , Burke, Louise , Cagle, Philip T., Đačić, Sanja , Guinee, Donald G., Raparia, Kirtee, Roden, Anja C. , Roy‐Chowdhuri, Sinchita , Sholl, Lynette M. , Beasley, Mary Beth , Roy-Chowdhuri, Sinchita , Hariri, Lida P. , Smith, Maxwell L. , Mino-Kenudson, Mari A. , Capelozzi, Vera Luíza , Churg, Andrew

Mayo Clinic

Annals of the American Thoracic Society | January 16, 2020 | Volume: 17 | Issue: 5 | Pages: 550-554

10.1513/annalsats.201910-801ps | PMID 31945306 Get It

Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN)
Aschenbrenner, Andrew J. , James, Bryan D. , Wang, Guoqiao , Lim, Yen Ying , Benzinger, Tammie L.S. , Cruchaga, Carlos , Goate, Alison , Xiong, Chengjie , Perrin, Richard J. , Buckles, Virginia, Berman, Sarah , Chhatwal, Jasmeer P. , Fagan, Anne M. , Farlow, Martin R. , O’Connor, Antoinette , Graff‐Radford, Neill R. , Gräber, Susanne, Martins, Ralph N. , Masters, Colin L. , Mori, Hiroshi , Noble, James M. , Salloway, Stephen , Morris, John C. , Bateman, Randall J. , Hassenstab, Jason , Network, Dominantly Inherited Alzheimer, Cruchaga, Carlos , O'Connor, Antoinette , Bateman, Randall J , Masters, Colin L , Xiong, Chengjie , Benzinger, Tammie L S , Hassenstab, Jason , Morris, John C , Aschenbrenner, Andrew J , Goate, Alison M , Berman, Sarah , McDade, Eric , Xiong, Chengjie , Allegri, Ricardo , Ghetti, Bernardino , Goldman, Jill , Karch, Celeste M. , Lee, Jae‐Hong , Schofield, Peter R. , Network, Dominantly Inherited Alzheimer, Noble, James M

Mayo Clinic

Alzheimer's & Dementia | January 16, 2020 | Volume: 16 | Issue: 1 | Pages: 219-228

10.1002/alz.12010 | PMID 31914221 Get It

AbstractIntroductionAlthough some members of families with autosomal dominant Alzheimer's disease mutations learn their mutation status, most do not. How knowledge of mutation status affects clinical disease progression is unknown. This study quantifies the influence of mutation awareness on clinical symptoms, cognition, and biomarkers.MethodsMutation carriers and non‐carriers from the Dominantly Inherited Alzheimer Network (DIAN) were stratified based on knowledge of mutation status. Rates of change on standard clinical, cognitive, and neuroimaging outcomes were examined.ResultsMutation knowledge had no associations with cognitive decline, clinical progression, amyloid deposition, hippocampal volume, or depression in either carriers or non‐carriers. Carriers who learned their status mid‐study had slightly higher levels of depression and lower cognitive scores.DiscussionKnowledge of mutation status does not affect rates of change on any measured outcome. Learning of status mid‐study may confer short‐term changes in cognitive functioning, or changes in cognition may influence the determination of mutation status.
An International Multicenter Evaluation of Type 5 Long QT Syndrome
Roberts, Jason D. , Asaki, S. Yukiko , Mazzanti, Andrea , Bos, J. Martijn , Tuleta, Izabela , Muir, Alison , Crotti, Lia , Kutyifa, Valentina , Shoemaker, M. Benjamin , Johnsrude, Christopher L. , Aiba, Takeshi , Marcondes, Luciana, Baban, Anwar , Udupa, Sharmila, Dechert, Brynn E. , Fischbach, Peter , Knight, Linda M., Kukavica, Deni , Stallmeyer, Birgit, Giudicessi, John R. , Spazzolini, Carla , Cadrin‐Tourigny, Julia , Simpson, Christopher S. , Roston, Thomas M. , Hajjaji, Imane El , Yousif, Maisoon D. , Gula, Lorne J. , Leong‐Sit, Peter , Chavali, Nikhil, Landstrom, Andrew P. , Marcus, Gregory M. , Dittmann, Sven , Wilde, Arthur A.M. , Behr, Elijah R. , Tfelt‐Hansen, Jacob , Kaski, Juan Pablo , Gow, Robert M., Aziz, Peter F. , Abrams, Dominic J. , Skinner, Jonathan R. , Kaufman, Elizabeth S. , Roden, Dan M. , Zaręba, Wojciech , Schulze‐Bahr, Eric , Etheridge, Susan P. , Priori, Silvia G. , Ackerman, Michael J. , Crotti, Lia , Behr, Elijah Raphael , Landstrom, Andrew P , Bos, Johan M , Tfelt-Hansen, Jacob , Skinner, Jonathan R , Abrams, Dominic J , Baban, Anwar , Kaski, Juan P , Johnsrude, Christopher , Mazzanti, Andrea , Cadrin-Tourigny, Julia , Zareba, Wojciech , Spazzolini, Carla , Priori, Silvia , Marcus, Gregory M , Krahn, Andrew D. , Aiba, Takeshi , Knight, Linda M., Vittinghoff, Eric , Shimamoto, Keiko , Tadros, Rafik , Duff, Henry J. , Wijeyeratne, Yanushi D. , Scheinman, Melvin M , Pérez, Marco , Drago, Fabrizio , Gollob, Michael H. , Shimizu, Wataru , Roden, Dan M. , Schwartz, Peter J.

Mayo Clinic

Circulation | January 16, 2020 | Volume: 141 | Issue: 6 | Pages: 429-439

10.1161/circulationaha.119.043114 | PMID 31941373 Get It

Background: Insight into type 5 long QT syndrome (LQT5) has been limited to case reports and small family series. Improved understanding of the clinical phenotype and genetic features associated with rare KCNE1 variants implicated in LQT5 was sought through an international multicenter collaboration. Methods: Patients with either presumed autosomal dominant LQT5 (N = 229) or the recessive Type 2 Jervell and Lange-Nielsen syndrome (N = 19) were enrolled from 22 genetic arrhythmia clinics and 4 registries from 9 countries. KCNE1 variants were evaluated for ECG penetrance (defined as QTc >460 ms on presenting ECG) and genotype-phenotype segregation. Multivariable Cox regression was used to compare the associations between clinical and genetic variables with a composite primary outcome of definite arrhythmic events, including appropriate implantable cardioverter-defibrillator shocks, aborted cardiac arrest, and sudden cardiac death. Results: A total of 32 distinct KCNE1 rare variants were identified in 89 probands and 140 genotype positive family members with presumed LQT5 and an additional 19 Type 2 Jervell and Lange-Nielsen syndrome patients. Among presumed LQT5 patients, the mean QTc on presenting ECG was significantly longer in probands (476.9±38.6 ms) compared with genotype positive family members (441.8±30.9 ms, P <0.001). ECG penetrance for heterozygous genotype positive family members was 20.7% (29/140). A definite arrhythmic event was experienced in 16.9% (15/89) of heterozygous probands in comparison with 1.4% (2/140) of family members (adjusted hazard ratio [HR] 11.6 [95% CI, 2.6–52.2]; P =0.001). Event incidence did not differ significantly for Type 2 Jervell and Lange-Nielsen syndrome patients relative to the overall heterozygous cohort (10.5% [2/19]; HR 1.7 [95% CI, 0.3–10.8], P =0.590). The cumulative prevalence of the 32 KCNE1 variants in the Genome Aggregation Database, which is a human database of exome and genome sequencing data from now over 140 000 individuals, was 238-fold greater than the anticipated prevalence of all LQT5 combined (0.238% vs 0.001%). Conclusions: The present study suggests that putative/confirmed loss-of-function KCNE1 variants predispose to QT prolongation, however, the low ECG penetrance observed suggests they do not manifest clinically in the majority of individuals, aligning with the mild phenotype observed for Type 2 Jervell and Lange-Nielsen syndrome patients.
Characteristics and quality of rotation-specific resident learning goals: a prospective study
Sawatsky, Adam P. , Halvorsen, Andrew J. , Daniels, Paul R. , Bonnes, Sara L. , Issa, Meltiady , Ratelle, John T. , Stephenson, Christopher R. , Beckman, Thomas J.

Mayo Clinic

Medical Education Online | January 16, 2020 | Volume: 25 | Issue: 1 | Pages: No page available

10.1080/10872981.2020.1714198 | PMID 31941433 Get It

Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline
Trabulsi, Edouard J. , Rosenkrantz, Andrew B. , Verma, Sadhna , Margolis, Daniel , Froemming, Adam T. , Oto, Aytekin , Milowsky, Matthew I. , Schlemmer, Heinz-Peter, Eiber, Matthias , Padhani, Anwar R. , Jain, Suneil , Pinto, Peter, Keegan, Kirk A., Porter, Christopher R., Jani, Ashesh B. , Kamradt, Jeffrey M., Sholes, Westley, Vargas, H. Alberto, Froemming, Adam, Rumble, R. Bryan , Jadvar, Hossein , Hope, Thomas A. , Pomper, Martin G. , Türkbey, Barış , Purysko, Andrei Saraiva , Morris, Michael J. , Choyke, Peter L. , Oldan, Jorge Daniel , Fanti, Stefano , Coleman, Jonathan , Bauman, Glenn

Mayo Clinic

Journal of Clinical Oncology | January 15, 2020 | Volume: 38 | Issue: 17 | Pages: 1963-1996

10.1200/jco.19.02757 | PMID 31940221 Get It

PURPOSE Provide evidence- and expert-based recommendations for optimal use of imaging in advanced prostate cancer. Due to increases in research and utilization of novel imaging for advanced prostate cancer, this guideline is intended to outline techniques available and provide recommendations on appropriate use of imaging for specified patient subgroups. METHODS An Expert Panel was convened with members from ASCO and the Society of Abdominal Radiology, American College of Radiology, Society of Nuclear Medicine and Molecular Imaging, American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology to conduct a systematic review of the literature and develop an evidence-based guideline on the optimal use of imaging for advanced prostate cancer. Representative index cases of various prostate cancer disease states are presented, including suspected high-risk disease, newly diagnosed treatment-naïve metastatic disease, suspected recurrent disease after local treatment, and progressive disease while undergoing systemic treatment. A systematic review of the literature from 2013 to August 2018 identified fully published English-language systematic reviews with or without meta-analyses, reports of rigorously conducted phase III randomized controlled trials that compared ≥ 2 imaging modalities, and noncomparative studies that reported on the efficacy of a single imaging modality. RESULTS A total of 35 studies met inclusion criteria and form the evidence base, including 17 systematic reviews with or without meta-analysis and 18 primary research articles. RECOMMENDATIONS One or more of these imaging modalities should be used for patients with advanced prostate cancer: conventional imaging (defined as computed tomography [CT], bone scan, and/or prostate magnetic resonance imaging [MRI]) and/or next-generation imaging (NGI), positron emission tomography [PET], PET/CT, PET/MRI, or whole-body MRI) according to the clinical scenario.
The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients
Kukla, Aleksandra , Hill, Jennifer M. , Merzkani, Massini , Bentall, Andrew , Lorenz, Elizabeth C. , Park, Walter D. , D’Costa, Matthew R. , Kudva, Yogish C. , Stegall, Mark D. , Shah, Pankaj, Hill, Jennifer, D'Costa, Matthew, Stegall, Mark D , D'Costa, Matthew , Bentall, Andrew , Park, Walter , Shah, Pankaj

Mayo Clinic

Transplantation Direct | January 15, 2020 | Volume: 6 | Issue: 2 | Pages: e524

10.1097/txd.0000000000000971 | PMID 32095510 Get It

Background. Glucagon-like peptide-1 receptor agonists (GLP1RA) have been shown to improve glucose control and diabetes-related comorbidities in patients without solid organ transplants. The effectiveness, safety, and tolerability of GLP1RA after kidney transplantation have not been adequately studied. Methods. We retrospectively reviewed data on kidney transplant recipients performed in our institution, who were initiated on GLP1RA either for the treatment of type 2 diabetes diagnosed before transplantation or posttransplant diabetes. We analyzed efficacy, safety, and the effect on kidney allograft function. Results. Seventeen kidney transplant recipients were initiated on GLP1RA therapy, 14 of which remained on the medication for at least 12 months. The use of GLP1RA had no significant impact on weight loss, but was associated with a significant reduction in the total daily insulin dose, from the median of 63 [interquartile range 43-113] IU to 44 [interquartile range 25-88] and reduction in the risk of hypoglycemia in patients who were on therapy for at least approximately 12 months. Kidney function remained stable and none of the recipients experienced acute rejection. Tacrolimus dose was not significantly changed. Five patients (29%) discontinued GLP1RA therapy—4 due to side effects and 1 due to uncontrolled hyperglycemia. Conclusions. GLP1RA may be a relatively safe and effective treatment for kidney transplant recipients with type 2 diabetes that allows for a reduction in insulin requirements. More studies are needed to determine whether the use of these agents will translate into an improvement in allograft and patient survival.
A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry
Du, Zhaohui , Weinhold, Niels , Song, Gregory, Rand, Kristin A. , Hwang, Amie E. , Sheng, Xin , Hom, Victor, Pawlish, Karen , Peters, Edward , Mohrbacher, Ann, Stram, Alexander , Berndt, Sonja I. , Blot, William J. , Stevens, Victoria L. , Goodman, Phyllis J. , Diver, W. Ryan , Hennis, Anselm , Nemesure, Barbara , Klein, Eric A. , Rybicki, Benjamin A. , Stanford, Janet L. , Witte, John S. , Signorello, Lisa B., John, Esther M. , Stroup, Antoinette M. , Stephens, Owen , Zangari, Maurizio , Hu, Jennifer J. , Nyante, Sarah J. , Carpten, John D. , Mehta, Jayesh, Wolf, Jeffrey L. , Martin, Thomas G. , Tomasson, Michael H. , Terebelo, Howard R. , Janakiraman, Nalini, Kolonel, Laurence N. , Auclair, Daniel , Chiu, Brian C.‐H. , Ziv, Elad , Vij, Ravi , Bernal‐Mizrachi, Leon , Morgan, Gareth J. , Zonder, Jeffrey A. , Huff, Carol Ann , Orlowski, Robert Z. , Conti, David V. , Haiman, Christopher A. , Orlowski, Robert Z. , John, Esther M , Klein, Eric A , Nyante, Sarah , Morgan, Gareth J , Ziv, Elad , Conti, David V , Berg, David Van Den , Ailawadhi, Sikander , Nooka, Ajay K. , Singhal, Seema , Bock, Cathryn Hufford , Stram, Alex , Casey, Graham , Kittles, Rick A. , Bernstein, Leslie , Rhee, Frits van , Olshan, Andrew F. , Zheng, Wei , Ziegler, Regina G. , Ingles, Sue A. , Press, Michael F. , Chanock, Stephen Jacob , Colditz, Graham A. , Fiala, Mark A. , Anderson, Kenneth C. , Marchand, Loı̈c Le , Stram, Daniel O. , Lonial, Sagar , Cozen, Wendy

Mayo Clinic

Blood Advances | January 14, 2020 | Volume: 4 | Issue: 1 | Pages: 181-190

10.1182/bloodadvances.2019000491 | PMID 31935283 Get It

Abstract Persons of African ancestry (AA) have a twofold higher risk for multiple myeloma (MM) compared with persons of European ancestry (EA). Genome-wide association studies (GWASs) support a genetic contribution to MM etiology in individuals of EA. Little is known about genetic risk factors for MM in individuals of AA. We performed a meta-analysis of 2 GWASs of MM in 1813 cases and 8871 controls and conducted an admixture mapping scan to identify risk alleles. We fine-mapped the 23 known susceptibility loci to find markers that could better capture MM risk in individuals of AA and constructed a polygenic risk score (PRS) to assess the aggregated effect of known MM risk alleles. In GWAS meta-analysis, we identified 2 suggestive novel loci located at 9p24.3 and 9p13.1 at P &lt; 1 × 10−6; however, no genome-wide significant association was noted. In admixture mapping, we observed a genome-wide significant inverse association between local AA at 2p24.1-23.1 and MM risk in AA individuals. Of the 23 known EA risk variants, 20 showed directional consistency, and 9 replicated at P &lt; .05 in AA individuals. In 8 regions, we identified markers that better capture MM risk in persons with AA. AA individuals with a PRS in the top 10% had a 1.82-fold (95% confidence interval, 1.56-2.11) increased MM risk compared with those with average risk (25%-75%). The strongest functional association was between the risk allele for variant rs56219066 at 5q15 and lower ELL2 expression (P = 5.1 × 10−12). Our study shows that common genetic variation contributes to MM risk in individuals with AA.
Head and Neck Mesenchymal Neoplasms With GLI1 Gene Alterations
Xu, Bin , Chang, Koping , Folpe, Andrew L. , Kao, Yu‐Chien , Wey, Shiuan-Li, Huang, Hsuan-Ying, Gill, Anthony J. , Wey, Shiuan-Li, Rooper, Lisa M. , Bishop, Justin A. , Dickson, Brendan C. , Lee, Jen‐Chieh , Antonescu, Cristina R.

Mayo Clinic

American Journal of Surgical Pathology | January 14, 2020 | Volume: 44 | Issue: 6 | Pages: 729-737

10.1097/pas.0000000000001439 | PMID 31934916 Get It

Soft tissue tumors with GLI1 gene fusions or amplifications have been recently described as a unique pathologic entity with an established risk of malignancy. We herein expand these findings by investigating a cohort of 11 head and neck lesions with GLI1 alterations, including 8 from the tongue, for their clinicopathologic and molecular features. The tumors commonly affected males in their 30s (male:female ratio 2.7:1; range: 1 to 65). Tumors showed a multinodular growth pattern, nested architecture separated by a delicate, arborizing vascular network, monotonous round to ovoid nuclei, and clear cytoplasm. Tumor protrusion into vascular spaces was common. Genetic alterations were investigated by fluorescence in situ hybridization and/or targeted RNA sequencing. Seven tumors harbored GLI1 fusions with the following partners: ACTB (n=4), PTCH1 (n=2), or MALAT1 (n=1). The remaining 4 cases showed coamplifications of GLI1 with CDK4 and MDM2 genes. Tumors were commonly positive for S100 protein and CD56. CDK4, MDM2, and STAT6 were positive in GLI1 -amplified tumors. Two of 6 patients with available follow-up (1 each with GLI1 amplification and PTCH1-GLI1 fusion) developed distant metastases. Both tumors showed a high mitotic index and tumor necrosis. The head and neck region, particularly tongue, is a common location for GLI1 -related mesenchymal tumors. Although a morphologic overlap was noted with the previously reported “pericytoma with t(7,12) translocation,” often occurring in the tongue, our findings expand the original findings, to include a more variable immunophenotype, propensity for late distant metastases, and alternative mechanisms of GLI1 oncogenic activation, such as various GLI1 fusion partners or GLI1 coamplifications with MDM2 and CDK4 genes.
Systematic Review and Meta-Analysis—Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma?
Azizi, Mounsif , Aydın, Ahmet Murat , Hajiran, Ali , Kumar, Ambuj , Peyton, Charles C. , Minhas, Suks , Sonpavde, Guru , Chahoud, Jad , Pagliaro, Lance C. , Lai, Andrew, Necchi, Andrea , Spiess, Philippe E.

Mayo Clinic

Journal of Urology | January 13, 2020 | Volume: 203 | Issue: 6 | Pages: 1147-1155

10.1097/ju.0000000000000746 | PMID 31928407 Get It